在ER阴性和HER2阳性乳腺癌中具有PIK3CA突变,具有阿波克林分化
Fumi Nozaki1, Yoko Nakanishi2, Yukari Hirotani2
1Division of Oncologic Pathology, Department of Pathology and Microbiology, Nihon University School of Medicine, 30-1, Oyaguchikami-cho, Itabashi-ku, Tokyo, 173- 8610, Japan. fuchinoue.fumi@nihon-u.ac.jp.
Breast cancer (Tokyo, Japan)
|February 23, 2026
概括
在阿波克林癌中发现了PIK3CA突变,包括ER阴性亚型. 这些突变驱动癌细胞的增殖,这表明向疗法可能有利于患有非分泌乳腺癌的患者.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 分子生物学分子生物学
背景情况:
- 针对PIK3CA突变乳腺癌的向治疗仅限于HR阳性,HER2阴性亚型.
- 阿波克林癌瘤 (阿波克林癌) 通常是ER阴性和HER2阳性/阴性,排除它在当前的PIK3CA向治疗中.
- 这项研究研究了阿波克林细胞中PIK3CA突变,特别是ER阴性亚型.
研究的目的:
- 为了确定PIK3CA突变在阿波克林癌的患病率.
- 评估PIK3CA突变在阿波克林癌细胞增殖中的功能意义.
- 探索PIK3CA向治疗在阿波克林大脑中的潜力.
主要方法:
- 在20个阿波克林细胞中分析了热点PIK3CA突变. 和70个没有特殊类型的侵入性乳腺癌 (IBC-NST) 样本.
- 通过siRNA利用PIK3CA的淘汰来比较阿波克林CA中的增殖. 有或没有PIK3CA突变的细胞系.
- 在MDA-MB-453 (ER-/HER2+/AR+),MFM223 (ER-/HER2-/AR+) 和HCC1428 (ER+/HER2-/AR-) 细胞系中比较的增殖率.
主要成果:
- PIK3CA突变在15%的阿波克林细胞中被发现. 和 2.9% 的 IBC-NST 病例.
- 在ER阴性,HER2阳性亚型中,约25%的阿波克林. 具有PIK3CA突变,而IBC-NST中为0%.
- 在MDA-MB-453和MFM223中,PIK3CA的淘汰显著降低了MDA-MB-453和MFM223的多发性. 细胞系. 细胞系. 细胞系.
结论:
- 皮克3CA突变存在于ER阴性和HER2阳性阿波克林细胞中.
- 这些突变在体外驱动了PIK3CA依赖的增殖.
- 异分离体的ca. 异分离体的ca. 患者可能从PIK3CA突变测试和向治疗中受益.
相关概念视频
The Ras Gene
7.4K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
7.4K
Abnormal Proliferation
5.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
mTOR Signaling and Cancer Progression
4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.9K
PI3K/mTOR/AKT Signaling Pathway
5.8K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.8K
Tumor Progression
7.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.5K
Cancers Originate from Somatic Mutations in a Single Cell
15.0K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
15.0K


